Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q3 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Symbol: ADVM on Nasdaq
Shares outstanding: 22,163,711
Price per share: $4.53
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares: 506,821
Total reported value: $2,295,899
Share change: 0
Number of holders: 1

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
TCG Crossover GP II, LLC	8.9%				1,871,482		TCG Crossover GP II, LLC	31 Mar 2025

As of 30 Sep 2025, 1 institutional investors reported holding 506,821 shares of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM). This represents 2.3% of the company’s total 22,163,711 outstanding shares.

Institutional Holders of Adverum Biotechnologies, Inc. - Common Stock, par value $0.0001 per share (ADVM) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q3	506,821	$2,295,899				$4.53	1
2025 Q2	506,821	$1,089,665				$2.15	1
2025 Q1	506,821	$2,214,808				$4.37	1
2024 Q4	506,821	$2,366,854				$4.67	1
2024 Q3	506,821	$3,557,883	-$13,777,212			$7.02	1
2024 Q2	2,515,161	$17,254,004	-$15,119,117			$6.86	2
2024 Q1	3,584,406	$50,683,501	-$61,426,429	$0	$0	$14.14	3
2023 Q4	63,952,123	$48,137,751	+$29,208,930	$2,033	$41,401	$0.75	58
2023 Q3	9,258,040	$13,886,957	-$57,160	$300	$53,250	$1.50	8
2023 Q2	65,473,558	$104,102,169	+$5,752,040		$89,517	$1.59	56
2023 Q1	61,330,272	$43,994,581	+$4,082,770	$0	$54,810	$0.72	53
2022 Q4	57,113,614	$33,094,280	-$6,720,531	$6,781	$241,765	$0.58	56
2022 Q3	58,514,356	$55,588,188	-$1,211,819	$10,000	$333,000	$0.95	71
2022 Q2	57,923,797	$69,503,540	-$6,740,043	$13,000	$452,000	$1.20	65
2022 Q1	62,129,137	$81,386,013	-$1,328,342	$170,000	$689,000	$1.31	80
2021 Q4	65,600,223	$115,457,496	-$8,005,558	$695,000	$2,013,000	$1.76	93
2021 Q3	60,745,381	$131,864,216	-$22,869,427	$1,471,000	$2,725,000	$2.17	104
2021 Q2	76,372,195	$267,298,634	-$216,443,659	$3,694,000	$3,339,000	$3.50	112
2021 Q1	95,100,769	$937,826,079	+$10,260,627	$10,466,000	$2,874,000	$9.86	130
2020 Q4	91,727,594	$994,393,988	-$15,916,336	$11,380,000	$7,151,000	$10.84	149
2020 Q3	95,005,426	$978,616,669	+$112,301,134	$4,233,000	$6,638,000	$10.30	155
2020 Q2	80,866,267	$1,688,476,259	+$34,645,758	$4,732,000	$14,879,000	$20.88	138
2020 Q1	79,766,651	$779,685,273	+$235,090,378	$917,000	$11,597,000	$9.77	122
2019 Q4	56,102,396	$646,294,236	+$34,199,902	$3,524,000	$11,848,000	$11.52	113
2019 Q3	48,795,904	$265,941,291	-$13,062,768	$5,747,000	$6,520,000	$5.45	96
2019 Q2	46,330,181	$548,504,478	+$95,425,198	$448,000	$1,227,000	$11.89	92
2019 Q1	39,651,773	$207,770,336	+$8,793,083		$0	$5.24	82
2018 Q4	38,236,900	$120,464,668	-$9,936,151	$0	$54,000	$3.15	81
2018 Q3	34,548,140	$209,015,688	-$12,757,058	$123,000	$667,000	$6.05	101
2018 Q2	36,661,531	$194,311,714	+$9,799,114	$187,000	$691,000	$5.30	99
2018 Q1	34,592,074	$200,631,035	+$91,767,435	$527,000	$2,640,000	$5.80	95
2017 Q4	19,222,404	$67,283,021	+$19,603,117	$43,000	$1,477,000	$3.50	63
2017 Q3	13,568,843	$49,464,022	+$3,294,250			$3.65	55
2017 Q2	13,013,490	$32,535,015	-$1,442,099			$2.50	59
2017 Q1	13,520,204	$36,507,138	+$2,264,287			$2.70	70
2016 Q4	15,093,296	$43,772,064	-$554,925			$2.90	78
2016 Q3	15,258,307	$62,679,851	-$936,870	$15,000		$4.11	73
2016 Q2	15,762,099	$49,806,686	+$49,052,794	$47,000		$3.16	74
2016 Q1	226,341	$1,170,000	+$1,138,992			$5.17	3